title: Trying to reduce ovarian damage in patients with Hodgkin lymphoma using GnRH agonists?
authors.forename: Kutluk
authors.initials: K
authors.lastname: Oktay
authors.forename: Murat
authors.initials: M
authors.lastname: Sonmezer
authors.forename: David
authors.initials: D
authors.lastname: Barad
authors.forename: Norbert
authors.initials: N
authors.lastname: Gleicher
mesh_terms: D000293:Adolescent; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008597:Menstrual Cycle / Q000187:drug effects*; D011247:Pregnancy; D018873:Pregnancy Rate; D016649:Primary Ovarian Insufficiency / Q000139:chemically induced / Q000517:prevention & control*; D016896:Treatment Outcome; D017329:Triptorelin Pamoate / Q000627:therapeutic use*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D005300:Fertility Agents, Female; D017329:Triptorelin Pamoate